Skip to content

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

A Muliticenter, Open Label Safety Study of 2 Doses of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed GERD

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00868296
Enrollment
58
Registered
2009-03-24
Start date
2006-03-31
Completion date
2008-03-31
Last updated
2010-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux

Keywords

Safety

Brief summary

The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) are eligible to participate in this study.

Interventions

DRUGpantoprazole

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 12 Months
Healthy volunteers
No

Inclusion criteria

* Successful completion of the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) Study.

Exclusion criteria

* Patients requiring chronic use of warfarin, carbamepazine, or phenytoin.

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period6 weeksPre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Criteria are as follows: Potassium ≤ 3.0 mEq/L or ≥ 6.2 mEq/L; Carbon dioxide \< 12 mEq/L or \> 35 mEq/L; Total bilirubin \> 1.5xULN; CPK \> 3xULN; Gastrin ≥ 600 pg/mL; Neutrophils \< 10% or \> 80%; Platelet count \< 100 x10 to the third power/ul or \> 600 x10 to the third power/ul; Urine protein albumin \> 2+ (dipstick) 100mg/dL or positive; Urine leukocyte esterase \> 2+ (dipstick) moderate or positive.
Growth Parameters Z-scores6 weeksZ-Score is a statistical measure to evaluate how a single data point compares to a standard. A Z-Score describes whether a mean is above or below the standard and how unusual the measurement is. Z-scores primarily range from -3 to +3. A Z-score of 0 indicates the same mean, \>0 a greater mean, and \<0 a lesser mean than the standard. In this study, infant growth parameters were compared to a standard defined by Centers for Disease Control's growth charts.

Countries

Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, South Africa, Switzerland, United States

Participant flow

Recruitment details

Patients were recruited worldwide March 2006 to February 2008.

Pre-assignment details

Patients were eligible for enrollment into the study after completion of either study 3001B3-331 (NCT00362609) or study 3001B3-333 (NCT00259012).

Participants by arm

ArmCount
Low Dose Pantoprazole
Patients who participated previously in study 3001B3-333 (NCT00259012) (infants) and weighed 2.5 to \<7 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 2.5 mg; those weighing ≥ 7 kg to ≤ 15 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 5 mg. (A patient's dose may have been increased from the dose used in the previous study at the start of this open label extension study to manage clinical symptoms) No patients who participated previously in study 3001B3-331 (NCT00362609) (pre-term/neonates) were included in the low dose group.
12
High Dose Pantoprazole
Patients who participated previously in study 3001B3-333 (NCT00259012) (infants) and weighed 2.5 to \<7kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 5 mg; those weighing ≥ 7 kg to ≤ 15 kg generally received pantoprazole sodium enteric-coated spheroid suspension daily 10 mg. (A patient's dose may have been increased from the dose used in the previous study at the start of this open label extension study to manage clinical symptoms.) All patients who participated previously in study 3001B3-331 (NCT00362609) (pre-term/neonates) received 2.5 mg (or higher, if the dose was increased at the start of this open label extension study to manage clinical symptoms) and were classified as part of the high dose group for analysis purposes.
46
Total58

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event02
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicLow Dose PantoprazoleHigh Dose PantoprazoleTotal
Age Continuous7.34 months
STANDARD_DEVIATION 3.06
5.55 months
STANDARD_DEVIATION 3.44
5.92 months
STANDARD_DEVIATION 3.42
Sex: Female, Male
Female
5 Participants21 Participants26 Participants
Sex: Female, Male
Male
7 Participants25 Participants32 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
8 / —30 / —
serious
Total, serious adverse events
1 / —2 / —

Outcome results

Primary

Growth Parameters Z-scores

Z-Score is a statistical measure to evaluate how a single data point compares to a standard. A Z-Score describes whether a mean is above or below the standard and how unusual the measurement is. Z-scores primarily range from -3 to +3. A Z-score of 0 indicates the same mean, \>0 a greater mean, and \<0 a lesser mean than the standard. In this study, infant growth parameters were compared to a standard defined by Centers for Disease Control's growth charts.

Time frame: 6 weeks

Population: Safety population (all patients with ≥1 dose of study drug) who also had baseline and end of study evaluations. Data point pairs were analyzed. All patients in study 3001B3-335 originated from study 3001B3-331 or -333 and baselines from the original study they were in were used.

ArmMeasureGroupValue (MEAN)Dispersion
Low Dose PantoprazoleGrowth Parameters Z-scoresLength - Baseline (n=12, 45)0.33 units on scaleStandard Deviation 1.11
Low Dose PantoprazoleGrowth Parameters Z-scoresLength - Final evaluation (n=12, 45)0.45 units on scaleStandard Deviation 1.29
Low Dose PantoprazoleGrowth Parameters Z-scoresWeight - Baseline (n=12, 46)-0.16 units on scaleStandard Deviation 1.15
Low Dose PantoprazoleGrowth Parameters Z-scoresWeight - Final evaluation (n=12, 46)-0.05 units on scaleStandard Deviation 1.33
Low Dose PantoprazoleGrowth Parameters Z-scoresHead circumference - Baseline (n=11, 45)0.31 units on scaleStandard Deviation 1.17
Low Dose PantoprazoleGrowth Parameters Z-scoresHead circumference - Final evaluation (n=11, 45)0.25 units on scaleStandard Deviation 1.21
High Dose PantoprazoleGrowth Parameters Z-scoresHead circumference - Baseline (n=11, 45)-1.06 units on scaleStandard Deviation 2.1
High Dose PantoprazoleGrowth Parameters Z-scoresLength - Baseline (n=12, 45)-1.63 units on scaleStandard Deviation 2.99
High Dose PantoprazoleGrowth Parameters Z-scoresWeight - Final evaluation (n=12, 46)-1.00 units on scaleStandard Deviation 1.73
High Dose PantoprazoleGrowth Parameters Z-scoresLength - Final evaluation (n=12, 45)-1.04 units on scaleStandard Deviation 2.52
High Dose PantoprazoleGrowth Parameters Z-scoresHead circumference - Final evaluation (n=11, 45)-0.62 units on scaleStandard Deviation 1.71
High Dose PantoprazoleGrowth Parameters Z-scoresWeight - Baseline (n=12, 46)-1.26 units on scaleStandard Deviation 1.9
Comparison: Between group comparison for change from baseline in length z-score.p-value: 0.857ANCOVA
Comparison: Between group comparison for change from baseline in weight z-score.p-value: 0.901ANCOVA
Comparison: Between group comparison for change from baseline in head circumference z-score.p-value: 0.807ANCOVA
Comparison: Final evaluation compared to baseline within group comparison for length z-score.p-value: 0.595t-test, 2 sided
Comparison: Final evaluation compared to baseline within group comparison for length z-score.p-value: 0.016t-test, 2 sided
Comparison: Final evaluation compared to baseline within group comparison for weight z-score.p-value: 0.347t-test, 2 sided
Comparison: Final evaluation compared to baseline within group comparison for weight z-score.p-value: 0.04t-test, 2 sided
Comparison: Final evaluation compared to baseline within group comparison for head circumference z-score.p-value: 0.892t-test, 2 sided
Comparison: Final evaluation compared to baseline within group comparison for head circumference z-score.p-value: 0.006t-test, 2 sided
Primary

Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period

Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance. Criteria are as follows: Potassium ≤ 3.0 mEq/L or ≥ 6.2 mEq/L; Carbon dioxide \< 12 mEq/L or \> 35 mEq/L; Total bilirubin \> 1.5xULN; CPK \> 3xULN; Gastrin ≥ 600 pg/mL; Neutrophils \< 10% or \> 80%; Platelet count \< 100 x10 to the third power/ul or \> 600 x10 to the third power/ul; Urine protein albumin \> 2+ (dipstick) 100mg/dL or positive; Urine leukocyte esterase \> 2+ (dipstick) moderate or positive.

Time frame: 6 weeks

Population: Patients who received ≥1 dose of pantoprazole and had laboratory test results. The number of patients (n) tested varied by test, variations shown (low dose, high dose): Carbon dioxide (n=7,26), CPK (n=12,42), Gastrin (n=9,25), Neutrophils (n=12,44), Platelet count (n=12,41), Urine protein albumin (n=10,38), Urine leukocyte esterase (n=10,38).

ArmMeasureGroupValue (NUMBER)
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodCarbon dioxide (mmol/L)0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodNeutrophils (1,000,000,000/L)1 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodCPK (mU/mL)0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodPlatelet count (1,000,000,000/L)0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodTotal bilirubin (µmol/L)0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodUrine protein albumin0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodGastrin (pg/mL)0 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodUrine leukocyte esterase1 patients
Low Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodPotassium (mmol/L)0 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodUrine leukocyte esterase3 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodPotassium (mmol/L)3 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodCarbon dioxide (mmol/L)1 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodTotal bilirubin (µmol/L)1 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodCPK (mU/mL)2 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodGastrin (pg/mL)1 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodNeutrophils (1,000,000,000/L)0 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodPlatelet count (1,000,000,000/L)2 patients
High Dose PantoprazoleNumber of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment PeriodUrine protein albumin1 patients

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026